Dihydroceramide Δ4-Desaturase 1 Is Not Involved in SARS-CoV-2 Infection

Biol Pharm Bull. 2022;45(10):1559-1563. doi: 10.1248/bpb.b22-00503.

Abstract

Dihydroceramide Δ4-desaturase 1 (DEGS1) enzymatic activity is inhibited with N-(4-hydroxyphenyl)-retinamide (4-HPR). We reported previously that 4-HPR suppresses severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry through a DEGS1-independent mechanism. However, it remains unclear whether DEGS1 is involved in other SARS-CoV-2 infection processes, such as virus replication and release. Here we established DEGS1 knockout (KO) in VeroE6TMPRSS2 cells. No significant difference was observed in virus production in the culture supernatant between wild-type (WT) cells and DEGS1-KO cells, although the levels of dihydroceramide (DHCer), a DEGS1 substrate, were significantly higher in DEGS1-KO cells than WT cells. Furthermore, the virus-induced cytopathic effect was also observed in DEGS1-KO cells. Importantly, the EC50 value of 4-HPR in DEGS1-KO cells was almost identical to the value reported previously in WT cells. Our results indicated the lack of involvement of DEGS1 in SARS-CoV-2 infection.

Keywords: N-(4-hydroxyphenyl) retinamide; dihydroceramide; dihydroceramide Δ4-desaturase 1; severe acute respiratory syndrome coronavirus 2.

MeSH terms

  • Animals
  • COVID-19*
  • Ceramides
  • Chlorocebus aethiops
  • Fatty Acid Desaturases
  • Fenretinide* / pharmacology
  • Humans
  • Oxidoreductases
  • SARS-CoV-2
  • Vero Cells

Substances

  • Ceramides
  • dihydroceramide
  • Fenretinide
  • Oxidoreductases
  • Fatty Acid Desaturases
  • DEGS1 protein, human